Comparison of structure, logP and P388 cytotoxicity of some phenyl and ferrocenyl cyclic chalcone analogues. Application of RP-TLC for logP determination of the ferrocenyl analogues

• Authors: Pál Perjési , Krisztina Takács-Novák , Zsuzsanna Rozmer , Pál Sohár , Richard Bozak , Theresa Allen
• Languages of publication: EN

Abstracts

EN

Cyclic chalcone analogues (2–5) and their ferrocenyl counterparts (6–10) were synthesized and their logP and P388 cyctotoxity were investigated. The structures of the newly synthesized compounds were confirmed by IR 1H and 13NMR spectroscopy. Comparison of conjugation and stereochemistry of the respective derivatives showed similar characteristics compared to ones with some higher degree of conjugation in the ferrocenyl series. Comparison of logP of the ferrocenyl derivatives determined by a validated RP-TLC method showed the ferrocenyl derivatives to have higher logP TLC. The results demonstrate that the differences in three dimensional shape, conjugation and lipophilicity do not have strong influence on the P388 cytotoxicity of the investigated phenyl (1−5) and ferrocenyl (6−10) enones. [...]

Keywords

EN

Cyclic chalcone analogues; Ferrocene; RP-TLC logP; P388 cytotoxicity; IR; NMR

• Publisher: De Gruyter Open
• Journal: Open Chemistry
• Year: 2012
• Volume: 10
• Issue: 5
• Pages: 1500-1505

Dates

published

1 - 10 - 2012

online

21 - 7 - 2012

Contributors

author

Pál Perjési

• Institute of Pharmaceutical Chemistry, University of Pécs, Pécs, 7634, Hungary

author

Krisztina Takács-Novák

• Institute of Pharmaceutical Chemistry, Semmelweis University, Budapest, 1092, Hungary

author

Zsuzsanna Rozmer

• Institute of Pharmaceutical Chemistry, University of Pécs, Pécs, 7634, Hungary

author

Pál Sohár

• Department of Chemistry, Eötvös Lóránd University (ELTE), and Protein Modelling Group ELTE-HAS, Budapest, 1117, Hungary

author

Richard Bozak

• Department of Chemistry, California State University Hayward, Hayward, CA, 94542, USA

author

Theresa Allen

• Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2H7, Canada

References

• [1] I. Kron, Z. Pudychová-Chovanová, B. Veliká, J. Guzy, P. Perjési, Monatsh. Chem. 143, 13 (2012) http://dx.doi.org/10.1007/s00706-011-0633-0[Crossref]
• [2] V. Zsoldos-Mády, O. Ozohanics, A. Csámpai, V. Kudar, D. Frigyes, P. Sohár, J. Organomet. Chem. 694, 4185 (2009) http://dx.doi.org/10.1016/j.jorganchem.2009.09.007[Crossref]
• [3] J.B. Harborne, In: V. Cody, E. Middleton Jr., E. Harborne (Eds.), Plant flavonoids in Biology and Medicine: Biochemical, pharmacological and structure-activity relationships (Alan R. Liss. Inc., New York, 1986) 15
• [4] J.R. Dimmock, D.W. Elias, M.A. Beazely, N.M. Kandepu, Curr. Med. Chem. 6, 1125 (1999)
• [5] M.L. Go, X. Wu, X.L. Liu, Curr. Med. Chem. 12, 483 (2005) http://dx.doi.org/10.2174/0929867053363153[Crossref]
• [6] J.R. Dimmock, N.M. Kandepu, A.J. Nazarali, T.P. Kowalchuk, N. Motaganahalli, J.W. Quail, P. Mykytiuk, G.F. Audette, L. Prasad, P. Perjési, T.M. Allen, C.L. Santos, J. Szydlowski, E. De Clercq, J. Balzarini, J. Med. Chem. 42, 1358 (1999) http://dx.doi.org/10.1021/jm9806695[Crossref]
• [7] J.R. Dimmock, G.A. Zello, E.O. Oloo, J.W. Quail, H-B. Kraatz, P. Perjési, K. Takács-Novák, F. Aradi, T.M. Allen, C.L. Santos, J. Balzarini, E. DeClerq, J.P. Stables, J. Med. Chem. 45, 3103 (2002) http://dx.doi.org/10.1021/jm010559p[Crossref]
• [8] P. Perjési, U. Das, E. De Clercq, J. Balzarini, M. Kawase, H. Sakagami, J.P. Stables, T. Loránd, Zs. Rozmer, J.R. Dimmock, Eur. J. Med. Chem. 43, 839 (2008) http://dx.doi.org/10.1016/j.ejmech.2007.06.017[Crossref]
• [9] A. Valkonen, K. Laihia, E. Kolehmainen, R. Kauppinen, P. Perjési, Struct. Chem. 23, 209 (2012) http://dx.doi.org/10.1007/s11224-011-9860-6[Crossref]
• [10] P. Perjési, T. Nusser, Gy. Tarczay, P. Sohár, J. Mol. Struct. 479, 13 (1999) http://dx.doi.org/10.1016/S0022-2860(98)00805-9[Crossref]
• [11] P. Perjési, Zs. Bayer, I. Ember, Anticancer Res. 20, 475 (2000)
• [12] K. Monostory, V. Tamási, L. Vereczkey, P. Perjési, Toxicology 184, 203 (2003) http://dx.doi.org/10.1016/S0300-483X(02)00578-4[Crossref]
• [13] Zs. Rozmer, T. Berki, P. Perjési, Toxicol. in Vitro 20, 1354 (2006) http://dx.doi.org/10.1016/j.tiv.2006.05.006[Crossref]
• [14] P. Perjési, J. Kubalkova, Z. Chovanova, M. Marekova, Zs. Rozmer, K. Fodor, Z. Chavkova, V. Tomeckova, J. Guzy, Pharmazie 63, 899 (2008)
• [15] C. Hansch, A. Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology (John Wiley and Sons, New York, 1979)
• [16] W.Y. Liu, T. Xie, Y.M. Liang, W.M. Liu, Y.X. Ma, J. Organometallic Chem. 627, 93 (2001) http://dx.doi.org/10.1016/S0022-328X(01)00717-3[Crossref]
• [17] C. Biot, Curr. Med. Chem. - Anti-Infective Agents 3, 135 (2004) http://dx.doi.org/10.2174/1568012043354008[Crossref]
• [18] S. Top, A. Vessières, C. Cabestaing, et al. J. Organometallic Chem. 500, 637 (2001)
• [19] R. Kovjazin, T. Eldar, M. Patya, A. Vanichkin, H.M. Lander, A. Novogrodsky, FASEB J. 17, 467 (2003)
• [20] E. Hillard, A. Vessieres, F. Le Bideau, D. Plazuk, D. Spera, M. Huche, G. Jaouen, Chem. Med. Chem. 1, 551 (2006)
• [21] S.V. Lindeman, R.E. Bozak, R.J. Hicks, S. Husebye, Acta Chem. Scand. 51, 966 (1997) http://dx.doi.org/10.3891/acta.chem.scand.51-0966[Crossref]
• [22] X. Wu, E. R.T. Tiekink, I. Kostetski, N. Kocherginsky, A. L.C. Tan, S. B. Khoo, P. Wilairat, M.-L. Go, Eur. J. Pharm. Sci. 27, 175 (2006) http://dx.doi.org/10.1016/j.ejps.2005.09.007[Crossref]
• [23] M.S. Tute, Lipophilicity: A History. In: R. Mannhold, H. Kubiny, H. Timmerman (Eds.) Methods and Principles in Medicinal Chemistry, Vol. 4 - V. Pliska, B. Testa, H. van de Waterbeemd, Lipophilicity in Drug Action and Toxicology (VHC Publishers, Inc., Weinheim, FRG, 1996) 7–26
• [24] K. Takács-Novák, P. Perjési, J. Vámos, JPC-J. Planar Chrom. 14, 42 (2001)
• [25] P. Perjési, M. Takács, E. Ősz, Z. Pintér, J. Vámos, K. Takács-Novák, J. Chromatogr. Sci. 43, 289 (2005) [Crossref]
• [26] Zs. Rozmer. P. Perjési, K. Takács-Novák, J. Planar Chrom. - Modern TLC 19, 124 (2006) http://dx.doi.org/10.1556/JPC.19.2006.2.7[Crossref]
• [27] M.H. Abraham, N. Benjelloun-Dakhama, J.M.R. Gola, W.E. Jr. Acree, W.S. Cain, J.E. Cometto-Muniz, New J. Chem. 24, 825 (2000) http://dx.doi.org/10.1039/b004291i[Crossref]
• [28] P. Sohár, P. Perjési, K.W. Törnroos, S. Husebye, A. Vértes, Gy. Vankó, R.E. Bozak, J. Mol. Struct. 524, 297 (2000) http://dx.doi.org/10.1016/S0022-2860(00)00380-X[Crossref]
• [29] O.A. Phillips, L.A. Nelson, E.E. Knaus, T.M. Allen, R. Fathi-Afshar, Drug Des. Deliv. 4, 121 (1989)
• [30] P. Perjési, A. Perjessy, E. Kolehmainen, E. Ősz, M. Samalikova, E. Virtanen, J. Mol Struct. 697, 41 (2004) http://dx.doi.org/10.1016/j.molstruc.2004.02.006[Crossref]
• [31] P. Perjési, J. Linnanto, E. Kolehmainen, E. Ősz, E. Virtanen, J. Mol. Struct. 740, 81 (2005) http://dx.doi.org/10.1016/j.molstruc.2004.10.013[Crossref]
• [32] A. Hoser, Z. Kaluski, H. Maluszynska, V.D. Orlov, Acta Crystallogr. B36, 1256 (1980) [Crossref]
• [33] Z. Kaluski, E. Skrzypczak-Jankun, V.D. Orlov, I.A. Borovoi, Bull. Acad. Pol. Sci., Ser. Sci. Chim. 26, 869 (1978)
• [34] P. Sohár, A. Csámpai, P. Perjési, Arkivok (V),114 (2003)
• [35] A. Katrusiak, M. Ratajczak-Sitarz, Z. Kaluski, V.D. Orlov, Acta Crystallogr. C43, 103 (1987)

Identifiers

DOI

10.2478/s11532-012-0088-0